Dicerna to Present Nedosiran Data at American Society of Nephrology (ASN) Kidney Week 2020 - Seite 3

Cautionary Note on Forward-Looking Statements

This press release includes forward-looking statements pertaining to the Company’s planned attendance and presentation at a virtual scientific conference, which will include discussion of the Company’s clinical results related to nedosiran and an insurance claims analysis for primary hyperoxaluria, as well as to our business and operations, including the discovery, development and commercialization of our product candidates and technology platform, and the therapeutic potential thereof, the success of our collaboration with partners and any potential future collaborations. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those risks identified under the heading “Risk Factors” included in our most recent Form 10-Q filing and in other future filings with the SEC. The forward-looking statements contained in this press release reflect Dicerna's current views with respect to future events, and Dicerna does not undertake and specifically disclaims any obligation to update any forward-looking statements.

GalXC and PHYOX are trademarks of Dicerna Pharmaceuticals, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201009005373/en/